5Vote!
Fund my Mutual Fund (Free subscription) | 11/05/2009
We restarted a position in Myriad Genetics (MYGN) as a long term "growth at good value" play about 6 weeks ago , despite a horrid technical condition on the chart. Since then the stock has just sort of hung around and done nothing, trading in a very tight range. I was hoping this quarter's earnings report would provide some "oomph" but it appears we have nothing. No need...
5Vote!
Salt Lake Tribune (Free subscription) | 11/05/2009
Utah's Myriad Genetics Inc. often warns investors that historically, the first quarter of each fiscal year is its weakest. And this year, Myriad's first quarter that ended Sept.
5Vote!
Salt Lake Tribune (Free subscription) | 11/05/2009
Utah's Myriad Genetics Inc. often warns investors that historically, the first quarter of each fiscal year is its weakest. And this year, Myriad's first quarter that ended Sept.
3Vote!
GuruFocus Updates (Free subscription) | 11/04/2009
By 10qk. Myriad Genetics Inc. ( MYGN ) filed Quarterly Report for the period ended 2009-09-30. Read more » »
5Vote!
San Diego Union (Free subscription) | 11/13/2009
Myriad Pharmaceuticals Inc. on Friday reported a smaller fiscal first-quarter loss on lower research costs after the company was spun off from Myriad Genetics Inc.
3Vote!
Sify (Free subscription) | 11/13/2009
Myriad Pharmaceuticals Inc. on Friday reported a smaller fiscal first-quarter loss on lower research costs after the company was spun off from Myriad Genetics Inc.
5Vote!
Seattle Times (Free subscription) | 11/13/2009
Myriad Pharmaceuticals Inc. on Friday reported a smaller fiscal first-quarter loss on lower research costs after the company was spun off from Myriad Genetics Inc.
5Vote!
Seattle Post-Intelligencer (Free subscription) | 11/13/2009
SALT LAKE CITY -- Myriad Pharmaceuticals Inc. on Friday reported a smaller fiscal first-quarter loss on lower research costs after the company was spun off from Myriad Genetics Inc.
7Vote!
Miami Herald (Free subscription) | 11/13/2009
Myriad Pharmaceuticals Inc. on Friday reported a smaller fiscal first-quarter loss on lower research costs after the company was spun off from Myriad Genetics Inc.
5Vote!
San Fransisco Chronicle (Free subscription) | 11/13/2009
Myriad Pharmaceuticals Inc. on Friday reported a smaller fiscal first-quarter loss on lower research costs after the company was spun off from Myriad Genetics Inc. In its first quarter as an independent company, the research and drug development company lost $... Drug development - Pharmaceutical drug - Pharmaceutical - Business - Biotechnology and Pharmaceuticals
3Vote!
Daily Advance - Business (Free subscription) | 11/13/2009
SALT LAKE CITY — Myriad Pharmaceuticals Inc. on Friday reported a smaller fiscal first-quarter...
3Vote!
Rocky Mount Telegram - Business (Free subscription) | 11/13/2009
SALT LAKE CITY — Myriad Pharmaceuticals Inc. on Friday reported a smaller fiscal first-quarter...
5Vote!
Seattle Times (Free subscription) | 11/13/2009
... prices and continue expanding internationally to combat declining U.S. profit.Agilent Technologies Inc., up $1.18 at $28.61The scientific instrument maker posted a sharply lower fourth-quarter profit, hurt by restructuring charges and a revenue decline.Walt Disney Co., up $1.39 at $30.44The company posted a surprise jump in profit and announced an executive job switch that might point to...
5Vote!
Star Tribune (Free subscription) | 11/13/2009
SALT LAKE CITY - Myriad Pharmaceuticals Inc. on Friday reported a smaller fiscal first-quarter loss on lower research costs after the company was spun off from Myriad Genetics Inc.In its first quarter as an independent company, the research and drug development company lost $10.6 million, or 44 cents per share. That compares to $11.6 million, or 48 cents per share, a year ago....
4Vote!
kansascity.com (Free subscription) | 11/13/2009
... and continue expanding internationally to combat declining U.S. profit.
Agilent Technologies Inc., up $1.18 at $28.61
The scientific instrument maker posted a sharply lower fourth-quarter profit, hurt by restructuring charges and a revenue decline.
Walt Disney Co., up $1.39 at $30.44
The company posted a surprise jump in profit and announced an executive job switch...
